Mylan And Biocon’s Semglee Insulin Glargine Approved In US
Product Deemed A Biologic By FDA; Launch May Be Imminent
Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.
